Making Breast Cancer Care More Inclusive

The majority of data and guidelines on breast cancer were derived from research done with white European women.

“I don’t experience the screening recommendations in the same way that white women do,” says Yvette Gullatt, chief diversity officer for the University of California system. “I experience breast cancer in Black women as highly aggressive and lethal. I’ve had white colleagues who were diagnosed with breast cancer and go to radiation in the morning, and are back at work by 10 a.m.; they never miss a day.”

Gullatt was a participant in WISDOM, or Women Informed To Screen Depending on Measures Of Risk, to improve the breast cancer treatment for Black women. “We need more studies like this because [researchers] need more data in order to diagnose and treat us better,” she says.
[time-brightcove not-tgx=”true”]

The WISDOM study was launched in 2016 by Dr. Laura Esserman with the hope of bringing a more personalized approach to figuring out each woman’s risk for the disease, plus tailor a screening and treatment program appropriate for that risk.

Esserman’s team is working with community activists to raise awareness about the benefits of clinical trials for Black women. This comes after many years of mistrusting the system, such as the Tuskeegee or Henrietta lacks cases. These cases involved Black patients being used as subjects in research trials without them knowing about the risks and benefits. Providing them with the opportunity to learn more about research trials is especially important, since about 25% of breast cancers among Black women are triple negative, a highly aggressive form that’s missing the locks to three hormone-based drug “keys” that have become effective weapons in fighting the disease in recent years. Without these locks, the drugs can’t work, and tumors grow more quickly and seed new growths in other parts of the body. Most of these cancers also start in younger Black women, under age 40, so they aren’t picked up because they aren’t getting mammograms yet, per current guidelines.

Rickie Fairley is a former marketing executive who survived breast cancer and works to increase education about WISDOM among Black women. She has mobilized other women to serve as a clearinghouse for those who aren’t as familiar with the facts about breast cancer risk among Black women or about research and clinical trials. “Right now, we are not empowering Black women, or women of color, to understand the importance of research,” she says, noting that many Black women are afraid to join research studies. “There’s not enough data about Black women. We’re trying to figure out how to change the language so that we’re not afraid anymore, so that we take the fear away from any kind of research and empower us to participate in it.”

As part of WISDOM’s recruitment, Esserman has also reached out to the VA health system in the U.S. to include female veterans whose Breast cancer riskIt could also be linked to their military service, as well environmental conditions. Lisa Edwards, a veteran who was discharged from the Army in 1989, says the study is an opportunity to raise awareness and resources for women’s health in the VA system in general. “As female veterans, we faced chemicals and exposure just as the men did,” she says. “But because our bodies react differently, I think in the future it may help researchers understand certain cancers from chemicals that react differently in women than in men.”

Esserman hopes that having a more tailored approach to figuring out a woman’s risk based on her biological and social situation will mean that more women get the screening schedule and treatment for managing their breast health that’s right for them.


Related Articles

Back to top button